Overview

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

Status:
Withdrawn
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Boehringer Ingelheim
Celgene
Treatments:
Albumin-Bound Paclitaxel
Nintedanib
Paclitaxel